Lactobacillus reuteri CRL1101 beneficially modulate lipopolysaccharide-mediated inflammatory response in a mouse model of endotoxic shock
Lactobacillus reuteri CRL1101 was found to reduce inflammatory and oxidative damage during endotoxic shock induced by lipopolysaccharide (LPS) administration in mice. This beneficial effect was related to the capacity of both the cell structure as well as their secreted products to act synergistical...
| Authors: | , , , , |
|---|---|
| Format: | article |
| Status: | Published version |
| Publication Date: | 2013 |
| Country: | Argentina |
| Institution: | Consejo Nacional de Investigaciones Científicas y Técnicas |
| Repository: | CONICET Digital (CONICET) |
| Language: | English |
| OAI Identifier: | oai:ri.conicet.gov.ar:11336/2816 |
| Online Access: | http://hdl.handle.net/11336/2816 |
| Access Level: | Open access |
| Keyword: | Lactobacillus Reuteri Crl1101 Anti-Inflammatory Activity Lps Secreted Factors https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
| Summary: | Lactobacillus reuteri CRL1101 was found to reduce inflammatory and oxidative damage during endotoxic shock induced by lipopolysaccharide (LPS) administration in mice. This beneficial effect was related to the capacity of both the cell structure as well as their secreted products to act synergistically to induce a tolerogenic profile in immune cells. The study supports the idea that, although probiotic microorganisms may exert their beneficial effects due to their well-known ability to modulate intestinal immunity, these effects are not restricted to the gastrointestinal tract. In addition, we demonstrated that the in vitro screening of lactobacilli strains is still a powerful approach to discriminate the potential probiotic bacteria for specific functions that could be later studied in animal models. From the systematic studies reported here, L. reuteri CRL1101, a strain with technological potential usefulness in dairy products, is proposed as novel probiotic candidate for the prevention and control of systemic inflammatory disorders. |
|---|